Turn Therapeutics Inc. Common Stock
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditi… Read more
Turn Therapeutics Inc. Common Stock (TTRX) - Total Assets
Latest total assets as of June 2025: $4.33 Million USD
Based on the latest financial reports, Turn Therapeutics Inc. Common Stock (TTRX) holds total assets worth $4.33 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Turn Therapeutics Inc. Common Stock - Total Assets Trend (2023–2024)
This chart illustrates how Turn Therapeutics Inc. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Turn Therapeutics Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Turn Therapeutics Inc. Common Stock's total assets of $4.33 Million consist of 53.6% current assets and 46.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $821.93K | 40.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2024)
This chart illustrates how Turn Therapeutics Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Turn Therapeutics Inc. Common Stock's current assets represent 53.6% of total assets in 2024, a decrease from 59.7% in 2023.
- Cash Position: Cash and equivalents constituted 42.6% of total assets in 2024, down from 58.7% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 38.0% in 2023.
- Asset Diversification: The largest asset category is intangible assets at 40.1% of total assets.
Turn Therapeutics Inc. Common Stock Competitors by Total Assets
Key competitors of Turn Therapeutics Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Turn Therapeutics Inc. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Turn Therapeutics Inc. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Turn Therapeutics Inc. Common Stock is currently not profitable relative to its asset base.
Turn Therapeutics Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.20 | - | - |
| Quick Ratio | 3.20 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $2.33 Million | - | - |
Turn Therapeutics Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Turn Therapeutics Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | $2.05 Million |
| Market Capitalization | $31.93K USD |
Valuation Analysis
Below Book Valuation: The market values Turn Therapeutics Inc. Common Stock's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Turn Therapeutics Inc. Common Stock's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Turn Therapeutics Inc. Common Stock (2023–2024)
The table below shows the annual total assets of Turn Therapeutics Inc. Common Stock from 2023 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.05 Million | +1.75% |
| 2023-12-31 | $2.01 Million | -- |